Arbitrator Voids Beckman's Sale of HPV IP to Ventana; Beckman's Business Not Affected | GenomeWeb
This update includes comment from Beckman Coulter.

NEW YORK (GenomeWeb News) — An arbitration panel has ruled that Beckman Coulter violated the terms of an original cross-license agreement between Institute Pasteur and Digene when it sold its human papillomavirus intellectual property to Ventana, Digene announced today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.